List of Excipients in Branded Drug DEPO-PROVERA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	DEPO-PROVERA	medroxyprogesterone acetate	0009-0746	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	DEPO-PROVERA	medroxyprogesterone acetate	0009-0746	METHYLPARABEN
Pharmacia & Upjohn Company LLC	DEPO-PROVERA	medroxyprogesterone acetate	0009-0746	POLYETHYLENE GLYCOL 3350
Pharmacia & Upjohn Company LLC	DEPO-PROVERA	medroxyprogesterone acetate	0009-0746	POLYSORBATE 80

DEPO-PROVERA Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Depo-Provera is a mature medroxyprogesterone acetate injectable franchise with limited opportunity for exclusivity based on the active ingredient. The stronger commercial opportunities are in excipient optimization, preservative-free presentations, low-volume subcutaneous delivery, device integration, supply-chain reliability, and access-oriented formulations. The core formulation uses established excipients, including polyethylene glycol 3350, polysorbate 80, sodium chloride, methylparaben, and propylparaben. Generic competition is established for the intramuscular product, while differentiated delivery and improved tolerability remain potential value drivers.

What is Depo-Provera and which formulations are commercially relevant?

Depo-Provera is the brand name associated with medroxyprogesterone acetate, a synthetic progestin used primarily for contraception. The principal U.S. products are:

Product	Active ingredient	Dose	Route	Presentation	Commercial role
Depo-Provera CI	Medroxyprogesterone acetate	150 mg/mL	Intramuscular	1 mL vial or prefilled syringe, depending on market	Established clinic-administered contraceptive
Depo-subQ Provera 104	Medroxyprogesterone acetate	104 mg/0.65 mL	Subcutaneous	Prefilled syringe	Lower-volume, patient-oriented delivery option

Depo-Provera CI is administered every 13 weeks. Depo-subQ Provera 104 is also administered on a quarterly schedule and uses a lower injection volume than the intramuscular product. FDA labeling identifies medroxyprogesterone acetate as a contraceptive administered on a fixed dosing schedule and includes warnings concerning bone mineral density, irregular bleeding, and delayed return to fertility after discontinuation (FDA, 2024a; FDA, 2024b).

The commercial distinction is important. A generic manufacturer competing on the intramuscular product faces a mature market and limited differentiation. A company developing a subcutaneous, prefilled, or device-enabled version can compete on administration convenience, procurement efficiency, and patient access.

What excipients are used in Depo-Provera injections?

The U.S. labeling for Depo-Provera CI identifies the following excipients per mL:

Excipient	Approximate labeled quantity	Primary formulation function
Polyethylene glycol 3350	28.0 mg	Vehicle and suspension medium
Polysorbate 80	2.41 mg	Wetting and dispersion aid
Sodium chloride	8.6 mg	Tonicity adjustment
Methylparaben	1.37 mg	Antimicrobial preservative
Propylparaben	0.15 mg	Preservative system
Water for injection	Quantity sufficient	Aqueous phase

Depo-Provera is a suspension rather than a solution. The excipient system must maintain uniform dispersion of medroxyprogesterone acetate particles, support syringeability, control sedimentation, limit aggregation, and preserve dose uniformity during storage and administration.

Why polyethylene glycol 3350 matters

Polyethylene glycol 3350 is the dominant nonaqueous excipient in the formulation. It contributes to vehicle viscosity and suspension behavior. Its concentration affects:

• Particle settling rate.
• Redispersibility after storage.
• Injection force.
• Needle compatibility.
• Sedimentation volume.
• Dose recovery from vials and syringes.

A reformulator cannot assume that reducing polyethylene glycol improves the product. Lower viscosity may improve injection force but can increase sedimentation or produce a less uniform dose. Higher viscosity may improve suspension stability but create administration problems, especially through narrow-gauge needles or wearable delivery systems.

Why polysorbate 80 matters

Polysorbate 80 helps wet medroxyprogesterone acetate particles and reduce interfacial aggregation. Its concentration is commercially relevant because polysorbate 80 can undergo oxidation and hydrolysis, potentially generating degradants or affecting particle behavior during long-term storage.

A generic manufacturer should control:

• Peroxide content in incoming polysorbate 80.
• Fatty-acid composition.
• Lot-to-lot variability.
• Interaction with packaging materials.
• Effects on particle-size distribution and suspension stability.

A pharmaceutical-grade polysorbate 80 supply program with defined impurity controls can be a competitive advantage even where the excipient itself is not patentable.

Why methylparaben and propylparaben matter

The combination of methylparaben and propylparaben provides antimicrobial preservation for a multidose or vial-based product. The combination also creates a potential differentiation pathway because some markets, institutions, and patient groups prefer preservative-free products where technically and economically feasible.

Removing parabens would require a new microbial-control strategy. Options include:

• A single-dose presentation.
• A prefilled syringe.
• A sterile, closed-device configuration.
• A validated alternative preservative.
• A container-closure system that reduces repeated access.

A preservative-free product would not automatically be clinically superior. It would need to demonstrate sterility assurance, stability, compatibility, and acceptable manufacturing cost.

What excipient strategy is most attractive for Depo-Provera competitors?

The most practical strategy is not a wholesale reformulation. It is a staged platform strategy that preserves the established suspension behavior while targeting specific commercial weaknesses.

Strategy 1: Optimize the existing suspension

A generic manufacturer can use the reference formulation as the baseline and improve manufacturing robustness through:

• Tighter particle-size specifications.
• Improved wetting and homogenization.
• Lower variability in polysorbate 80.
• Better control of suspension viscosity.
• Reduced vial or syringe residual volume.
• More consistent resuspendability.
• Improved injection-force performance.

This strategy is compatible with an abbreviated regulatory pathway when the product remains pharmaceutically equivalent and therapeutically equivalent to the reference product. The principal value lies in yield, batch release, complaint reduction, and manufacturing reliability rather than new clinical claims.

Strategy 2: Develop a preservative-free single-dose product

A preservative-free version could target public-sector tenders, reproductive-health programs, and institutions with preservative-reduction policies. The likely presentation would be a single-dose prefilled syringe or single-dose vial.

The main technical requirements are:

Development issue	Commercial implication
Sterility assurance	Higher manufacturing and container-closure requirements
Product stability	May require new packaging and extractables/leachables work
Dose uniformity	Critical for a low-volume suspension
Device compatibility	Determines syringe, needle, and administration costs
Microbial control	Single-dose format can replace chemical preservation
Regulatory pathway	May require a new drug application or supplemental approval depending on formulation differences

This opportunity is more defensible than a simple generic because the value proposition combines formulation, packaging, and delivery-system claims.

Strategy 3: Improve subcutaneous delivery

Depo-subQ Provera 104 creates a platform for delivery innovation. Potential improvements include:

• Lower injection force.
• Smaller needle gauge.
• Reduced injection volume.
• Prefilled syringe optimization.
• Autoinjector or on-body injector compatibility.
• Improved suspension uniformity after storage.
• More reliable dose delivery by non-health-care personnel.

The main constraint is the physical behavior of a particulate suspension. Autoinjectors impose requirements for viscosity, force, needle geometry, injection duration, and device dead volume. A formulation that works in a conventional syringe may fail in an autoinjector because of high break-loose force or inconsistent flow.

What formulations are protected by Depo-Provera patents?

The original compound, medroxyprogesterone acetate, is an old active pharmaceutical ingredient, and the principal product patents associated with the original franchise are not the primary source of present-day market protection. Commercial diligence should focus on later formulation, presentation, device, manufacturing, and method-of-use rights rather than compound exclusivity.

IP category	Relevance to Depo-Provera	Current commercial significance
Compound patents	Medroxyprogesterone acetate	Generally legacy protection
Suspension formulation patents	Vehicle, particle size, wetting, stability	Potential value for differentiated products
Subcutaneous formulation patents	Lower dose and alternate route	Relevant to Depo-subQ-type products
Device patents	Prefilled syringes, autoinjectors, safety systems	Potential barrier to device-enabled entry
Manufacturing patents	Particle engineering, sterile filling, suspension processing	May protect process efficiency
Method-of-use patents	Contraceptive dosing or patient populations	Limited value if expired or not listed
Packaging patents	Container closure and dose delivery	Usually narrow but commercially relevant

The FDA Orange Book is central to evaluating listed patents and regulatory exclusivity for approved U.S. products. Generic applicants may submit Paragraph IV certifications against listed patents, but the practical significance depends on the patent’s enforceability, expiration, and whether the reference product has listed claims covering the proposed generic product (FDA, 2024c).

No compound-level exclusivity should be assumed for a new entrant. The stronger route to protection is a patent family covering a specific excipient ratio, particle-size distribution, low-volume suspension, preservative-free container, delivery device, or manufacturing process. Such claims must be drafted around measurable product attributes and supported by comparative stability or administration data.

When does Depo-Provera lose exclusivity?

Depo-Provera’s active ingredient is long past the period of ordinary small-molecule compound exclusivity. The U.S. market is therefore governed mainly by generic approval, product quality, manufacturing scale, contracts, branding, and any surviving formulation or device rights.

The commercial timeline is:

Milestone	Impact
Original approval of medroxyprogesterone acetate injectable products	Established the reference product
Expiration of legacy compound and early formulation rights	Opened the market to generic development
Approval of injectable ANDAs	Created direct price competition
Introduction of subcutaneous delivery	Added a differentiated route and presentation
Current market	Competition centers on supply, procurement, devices, and access

FDA regulatory exclusivity differs from patent exclusivity. A product may have no remaining meaningful patent barrier but still have product-specific regulatory protections, or it may have no material exclusivity at all. For a mature injectable, the principal entry risks are usually manufacturing readiness, sterile-facility capacity, bioequivalence or equivalence requirements, and supply-chain execution.

Which companies are challenging or competing with Depo-Provera?

The competitive field includes:

1. Generic manufacturers of medroxyprogesterone acetate injectable suspension.
2. Manufacturers of branded or authorized-generic products.
3. Developers of subcutaneous medroxyprogesterone acetate.
4. Long-acting contraceptive competitors using etonogestrel, levonorgestrel, or intrauterine delivery.
5. Public-health suppliers serving institutional and global procurement channels.

Generic injectable competition is likely to be more price-sensitive than differentiated subcutaneous competition. Long-acting reversible contraceptives, including implants and intrauterine systems, compete on duration, reversibility, administration setting, and patient preference rather than excipient composition alone.

How does Depo-Provera compare with other contraceptive products?

Product category	Administration interval	Excipient opportunity	Main competitive advantage
IM medroxyprogesterone acetate	About 13 weeks	Suspension stability and low-cost filling	Established use and broad familiarity
SC medroxyprogesterone acetate	About 13 weeks	Device compatibility and low injection force	Potentially easier administration
Etonogestrel implant	Up to several years	Polymer matrix and implant process	Long duration
Levonorgestrel IUD	Several years	Polymer reservoir and release control	Local delivery and long duration
Combined oral contraceptives	Daily	Tablet excipient and packaging strategy	User-controlled dosing

Depo-Provera’s commercial advantage is the quarterly schedule. Its disadvantages include injection dependence, irregular bleeding, delayed return to fertility, and bone mineral density concerns identified in FDA labeling. Excipient improvements cannot eliminate those active-drug risks, but better delivery can reduce administration friction.

What FDA regulatory pathway applies to a new Depo-Provera competitor?

A conventional generic version generally proceeds through an ANDA if it can demonstrate pharmaceutical equivalence, bioequivalence or applicable equivalence, and compliance with FDA quality requirements. A materially different formulation, route, device, concentration, or preservative system may require a different regulatory strategy.

Key regulatory issues include:

• Equivalent strength of medroxyprogesterone acetate.
• Equivalent dosage form and route.
• Particle-size distribution.
• Suspension uniformity.
• Redispersibility.
• Sterility and bacterial endotoxin limits.
• Preservative effectiveness where applicable.
• Container-closure integrity.
• Injection-force and syringeability data.
• Stability under labeled storage conditions.
• Device-drug combination requirements for prefilled or automated systems.

For a suspension, the formulation is part of the product’s performance. A manufacturer cannot treat excipients as interchangeable commodities without testing their impact on particle wetting, sedimentation, viscosity, syringeability, and dose uniformity.

What manufacturing and intellectual-property barriers exist?

The main barriers are technical and operational:

• Sterile suspension manufacturing.
• Reliable particle-size control.
• Uniform dispersion at commercial batch scale.
• Homogeneous filling into low-volume containers.
• Preservative assay and preservative-effectiveness control.
• Long-term stability of polysorbate 80.
• Compatibility with prefilled syringes and elastomeric components.
• Consistent injection force.
• Supplier qualification for pharmaceutical-grade excipients.
• Capacity at an approved sterile manufacturing site.

A company seeking defensible IP should combine formulation claims with process and presentation claims. A patent covering only a broad excipient class may be vulnerable to design-around. More useful claim structures may define:

• A specified medroxyprogesterone acetate particle-size range.
• A polyethylene glycol-to-polysorbate ratio.
• A sedimentation or redispersibility profile.
• A preservative-free single-dose suspension.
• A defined injection-force range.
• A prefilled syringe or autoinjector containing the suspension.
• A manufacturing sequence that produces a defined suspension profile.

What commercial opportunities exist in the Depo-Provera market?

The most credible opportunities are:

Generic IM product

This is the lowest-risk entry path but also the most exposed to price erosion. Success depends on manufacturing cost, procurement access, reliable supply, and regulatory execution.

Preservative-free presentation

A single-dose preservative-free product could support institutional and patient-segment differentiation. The commercial case depends on whether buyers will pay for the presentation and whether the added packaging cost is offset by procurement preference.

Subcutaneous and self-administration platform

A prefilled, low-force subcutaneous product offers the strongest potential for differentiation. Device integration may support higher margins and reduce reliance on clinic administration.

Global health and public-sector supply

Quarterly injectable contraception has relevance for public-health procurement. Suppliers with validated sterile capacity, dependable cold-chain or controlled-room-temperature logistics, and competitive tender pricing can compete even without strong patent exclusivity.

Excipient supply and contract manufacturing

Specialized suppliers can create value through pharmaceutical-grade polyethylene glycol 3350, low-peroxide polysorbate 80, preservative systems, suspension-processing services, and sterile filling. Contract manufacturers with experience in injectable suspensions may have more practical leverage than companies holding broad formulation patents.

How strong is the Depo-Provera patent estate?

The patent estate is strongest where it covers a specific modern presentation rather than the underlying contraceptive molecule. Legacy compound protection is not a meaningful barrier. Formulation and device claims may still affect a particular product, but their value depends on claim scope, expiration, listing status, prosecution history, and the exact proposed generic or follow-on product.

Overall assessment:

Factor	Assessment
Compound exclusivity	Low
Legacy formulation exclusivity	Low to moderate, depending on jurisdiction and claim status
Current generic entry barrier	Primarily regulatory and manufacturing
Subcutaneous/device differentiation	Moderate opportunity
Excipient-only patent strength	Usually limited unless tied to measurable performance
Commercial value of supply reliability	High in institutional markets
Litigation exposure	Product- and jurisdiction-specific

Key Takeaways

• Depo-Provera is a mature medroxyprogesterone acetate injectable franchise with limited compound-level exclusivity.
• The core excipient system includes polyethylene glycol 3350, polysorbate 80, sodium chloride, methylparaben, propylparaben, and water for injection.
• The main technical challenge is maintaining a stable, uniform suspension with acceptable injection force and dose recovery.
• A conventional IM generic is commercially feasible but likely exposed to price competition.
• Preservative-free single-dose packaging is a practical differentiation route.
• Subcutaneous delivery, prefilled syringes, and autoinjectors offer stronger commercial and IP opportunities.
• The most defensible patents are likely to cover defined suspension properties, formulation ratios, devices, packaging, or manufacturing processes.
• Current competitive risk is driven more by sterile manufacturing, regulatory approval, supply reliability, and procurement access than by the original active-ingredient patent estate.

FAQs

Can polyethylene glycol 3350 be replaced in a Depo-Provera generic?

It may be technically replaceable, but substitution would require development and regulatory support demonstrating equivalent suspension performance, stability, syringeability, and dose uniformity.

Is a preservative-free Depo-Provera formulation commercially viable?

Yes, particularly in a single-dose prefilled syringe. The commercial case depends on sterile manufacturing cost, institutional demand, packaging performance, and regulatory requirements.

Can Depo-Provera be delivered through an autoinjector?

Potentially, but the suspension’s particle size, viscosity, sedimentation, needle compatibility, and injection force must be compatible with the selected device.

Do excipients create patent protection for a Depo-Provera competitor?

Excipients alone rarely create strong protection. Patent value increases when the excipient system is linked to measurable performance, such as improved redispersibility, reduced injection force, extended stability, or device compatibility.

What is the largest commercial risk for a Depo-Provera generic?

The largest risk is usually price compression combined with sterile manufacturing and supply interruptions. A differentiated subcutaneous, preservative-free, or device-enabled product can reduce direct price competition.

References

1. U.S. Food and Drug Administration. (2024a). Depo-Provera CI (medroxyprogesterone acetate injectable suspension) prescribing information. Pfizer Inc.

2. U.S. Food and Drug Administration. (2024b). Depo-subQ Provera 104 (medroxyprogesterone acetate injectable suspension) prescribing information. Pfizer Inc.

3. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024d). Abbreviated new drug application submissions: Refuse-to-receive standards. U.S. Department of Health and Human Services.

5. World Health Organization. (2022). Medical eligibility criteria for contraceptive use (6th ed.). World Health Organization.

6. United States Pharmacopeia. (2024). General chapter <729>: Globule size distribution in lipid injectable emulsions. United States Pharmacopeial Convention.